Rheumatology News

The U.S. Supreme Court ruled 5-4 on Thursday that members of the Sackler family cannot be protected from future lawsuits for their roles in the opioid epidemic.

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more.

The risk-benefit profile of upadacitinib for rheumatoid arthritis “remains favorable” through 5 years, according to data published in The Journal of Rheumatology.

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

In this episode, we dive into the story of aspirin and the development of ibuprofen, ending with the experiments that showed the mechanism of how aspirin actually works.

Bimekizumab treatment for psoriatic arthritis demonstrated rapid, clinically meaningful improvements to patient reported outcomes that were sustained up to 1 year, according to data published in Rheumatology.

A long-term safety analysis of filgotinib for moderate-to-severe rheumatoid arthritis demonstrated potential dose-dependent risks for herpes zoster, malignancies and all-cause mortality in patients aged 65 and older, according to data.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate significant improvement vs. those who receive placebo at week 24, according to data presented at the EULAR 2024 Congress.

In this video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, highlights what he describes as “an outstanding roundtable” in the June issue on advanced practice providers’ expanding role in rheumatology care.